Umifenovir in Hospitalized COVID-19 Patients

Launched by SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES · Apr 14, 2020

Keywords

ClinConnect Summary

Umifenovir is a component derived from indole, which has showed positive efficacy in inhibition of virus-to-host cell attachment in different groups of influenza, and type C hepatitis virus. Another study in 2008 also corroborated the anti-viral effect of Arbidol on SARS-CoV in the cell cultures. Recent works of L. Deng and other colleagues in 11th march 2020 revealed that COVID-19 patients under the treatment of Arbidol Combined with LPV/r had a significant clinical improvement in comparison to patients administrated with LPV/r alone. A small trial has illustrated that COVID-19 infected ca...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18
• • COVID-19 Confirmed Cases (Either RT-PCR or CT Scan Confirmed).
• • Tympanic Temperature of ≥37.5 AND at least one of the following: Cough, Sputum production, nasal discharge, myalgia, headache or fatigue) on admission.
• • Time of onset of the symptoms should be acute ( Days ≤ 10).
• • SpO2 ≤ 93%
• • Respiratory Rate ≥ 22
• Exclusion Criteria:
• • Refusal to participate expressed by patient or legally authorized representative if they are present.
• • Patients with prolonged QT or PR intervals, Second or Third Degree heart block, Arrhythmias including torsade de pointes
• • Patients using drugs with potential interaction with Umifenovir Hydroxychloroquine, Lopinavir/Ritonavir or Interferon-β 1a.
• • Pregnant or lactating women.
• • History of alcohol or drug addiction in the past 5 years.
• • Blood ALT/AST levels \> 5 times the upper limit of normal on laboratory results.